reviewTop 1% cited
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Bone · 2017 · Vol. 105 · pp. 11–17
Elena Tsourdi(Technische Universität Dresden)Bente Langdahl(Aarhus University Hospital)Martine Cohen‐Solal(Inserm)Bérengère Aubry‐Rozier(University of Lausanne)Erik Fink Eriksen(Oslo University Hospital)Núria Guañabens(Hospital Clínic de Barcelona)Barbara Obermayer‐Pietsch(Medical University of Graz)Stuart H. Ralston(Western General Hospital)Richard Eastell(University of Sheffield)M. Carola Zillikens✉(Erasmus MC)
Bone health and treatmentsBone health and osteoporosis researchBone Metabolism and DiseasesDenosumabDiscontinuationMedicineOsteoporosisPosition statementStatement (logic)Systematic reviewIntensive care medicineInternal medicineMEDLINE
MeSH terms
DenosumabDiphosphonatesHumansOsteoporosisSocieties, MedicalBiomarkersBone DensityBone RemodelingWithholding Treatment
Funding
- Medical Research Council
Citations
481
FWCI
23.55
field-weighted impact
References
40
Percentile
100%
vs. same field & year
Citations per year
Cited by
American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update
Journal of Oral and Maxillofacial Surgery · 2022 · 989 citations
References
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Journal of Bone and Mineral Research · 2015 · 649 citations
Bisphosphonates: The first 40years
Bone · 2011 · 1,093 citations
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Journal of Bone and Mineral Research · 2011 · 692 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.